Brief: Immunogen Presents Findings From Expansion Cohorts In Phase 1B/2 Study Of Pivekimab Sunirine With Vidaza® And Venclexta® In Acute Myeloid Leukemia At Ash

ImmunoGen

10/12/2022 15:32

Dec 10 (Reuters) - ImmunoGen Inc  IMGN.O :
    * IMMUNOGEN PRESENTS FINDINGS FROM EXPANSION COHORTS IN
PHASE 1B/2
STUDY OF PIVEKIMAB SUNIRINE WITH VIDAZA® AND VENCLEXTA® IN ACUTE
MYELOID LEUKEMIA AT ASH
    * IMMUNOGEN INC - RECOMMENDED PHASE 2 DOSE WELL-TOLERATED;
DETERMINATION OF OPTIMAL VENCLEXTA DURATION ONGOING IN SEPARATE
COHORTS

Source text for Eikon:  ID:nBw3K66d6a 
Further company coverage:  IMGN.O 
 ((Reuters.Briefs@thomsonreuters.com;))